

CSD/BSE&NSE/2025-26

April 2, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Cautionary email received from the BSE regarding delay in intimation to Stock exchanges

Ref:

- 1) Email dated April 2, 2025, received from BSE**
- 2) Our disclosure dated July 12, 2024, to the stock exchanges.**

We would like to inform that the Company has received cautionary email from the BSE Limited (“BSE”) regarding delay in intimating to the Stock exchanges with respect to the appointment of Statutory Auditors of the Company on July 12, 2024.

The information as required in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), pertaining to the said cautionary email, is annexed as Annexure – 1.

Further, the email communication received from BSE is annexed as Annexure – 2.

In this connection, please note that the Company vide letter dated April 1, 2025 has intimated the stock exchanges about the cautionary email received from NSE on April 1, 2025.

Please note that we will ensure compliance with the disclosure requirements as required under Regulation 30 of the SEBI Listing Regulations.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
*Company Secretary, Compliance Officer
and Head-Legal*

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Annexure – 1

Sl. No.	Particulars	Details
1	Name of the authority	BSE Limited (“BSE”)
2	Nature and details of the action(s) taken, or order(s) passed by the Authority	The Company has received a cautionary email on April 2, 2025 from BSE with respect to the announcement submitted by the Company on July 12, 2024 regarding the appointment of Statutory Auditors of the Company.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	April 2, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Delay in intimating to the stock exchanges with respect to the appointment of Statutory Auditors of the Company, on July 12, 2024, i.e., intimation was not submitted within the prescribed timelines of 30 minutes of conclusion of the Board Meeting as per Regulation 30 of the SEBI Listing Regulations.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the financial, operation or other activities of the Company on account of the above.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



Cautionary Letter - Suven Pharmaceuticals Ltd

From Query lodr <query.lodr@bseindia.com>

Date Wed 2025-04-02 15:37

CAUTION: This email originated from outside of Suven Pharmaceuticals Limited. Do not click links or open attachments unless you recognize the sender and know the content is safe. Please also read the sender email address carefully.

LIST/COMP/JP/19/2025-26

Date: April 2, 2025

To,
Company Secretary/ Compliance Officer
Suven Pharmaceuticals Ltd (543064)

Sub:
Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on July 12, 2024 regarding to appointment of Statutory Auditor of the Company.

As per Regulation 30 read with sub-para 7 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in case of appointment of directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), senior management, Auditor and Compliance Officer, the event shall be disclosed to the Stock Exchanges by the listed entities within 30 minutes of conclusion of the Board Meeting.

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of 30 minutes of conclusion of the Board Meeting as per sub-para 7 of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team
BSE Limited
P J Towers, Dalal Street,

Mumbai - 400001, India
www.bseindia.com
Tel: 022 2272 8561 / 8475



This mail is classified as '**CONFIDENTIAL**' by query.lodr on April 02, 2025 at 15:37:29.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects. DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.

Confidentiality Notice:

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please delete the message and any attachments from your Inbox.